Compare Agilent Technologies Inc (A) vs HCA Health Inc (HCA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs HCA Health Inc — how do they compare? Agilent Technologies Inc trades at $128.23 (market cap $37.04B), while HCA Health Inc trades at $408.84 (market cap $93.86B). The key difference: HCA Health Inc is far larger — about 2.5× Agilent Technologies Inc's market cap, and Agilent Technologies Inc pays the higher dividend (0.78%). Which is the better fit depends on your goals.
| A | HCA | |
|---|---|---|
Market Cap | $37.04B | $93.86B |
Sector | Health | Health |
52-Week High | $157.20 | $545.13 |
52-Week Low | $110.24 | $334.32 |
Enterprise Value | $38.59B | $142.77B |
Dividend Yield | 0.78% | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
HCA Healthcare trades at $423.11, up 3.07% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with revenue growth to $75.6B in 2025 and consistent earnings beats. Recent news highlights capacity expansion and gene therapy advancements. Technical indicators suggest bullish trends, though RSI signals potential overbought conditions near-term.
Outlook remains positive given earnings momentum and strategic investments, but risks include high debt levels and healthcare regulatory pressures. Analyst consensus targets $493 with 65% buy ratings, indicating upside potential from current levels amid manageable execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →
